OPHT Ophthotech

OPHTHOTECH 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Ophthotech Corporation – (OPHT)

NEW ORLEANS--(BUSINESS WIRE)--

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Ophthotech Corporation (NasdaqGS: OPHT). Investor losses must relate to purchases of the Company’s shares between May 11, 2015 and December 12, 2016. This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of Ophthotech and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 13, 2017.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
11/03/2017

Underlying

OPHTOphthotech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ophthotech

Free Trial
OPHT OPHTHOTECH

OPHTHOTECH CORP. sees a downgrade to Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of OPHTHOTECH CORP. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date February 1, 2019, the closing price was USD 1.25 and its target pr...

02/02/19 February 2, 2019 6 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech Reports First Quarter 2018 Financial and Operating Results

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update. “We continue to build on our Zimura program with on-going clinical trials in wet age related macular degeneration (AMD) with patient recruitment completed and topline data expected by the end of 2018, in geographic atrophy secondary to dry AMD where recruitment is on-track for topline data in the second half of 2019 and in autosomal recessiv...

May 9, 2018 1 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Tria...

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. A total of 64 patients have been enrolled into this dose-ranging, open-label, ...

May 1, 2018 1 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech Corporation to Report First Quarter 2018 Financial Results ...

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. To participate in this conference call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 2075643. A live, listen-only ...

May 1, 2018 1 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech to Present at the Cowen and Company 38th Annual Health Care...

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20 a.m. Eastern Time. Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations section on the Ophthotech website at www.ophthotech.com. An archived replay of the webcast will be availa...

March 6, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch